Data from our laboratory, shown in Figure 2A, demonstrate that both the NF-κB inhibitor BAY 11-7085 and the proteasome inhibitor MG132 markedly reduce XIAP expression in PC-3 prostate cancer cells. This evidence concerns the gene NFKB1 and prostate cancer.